PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
IRON vs. MURA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between IRON and MURA is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

IRON vs. MURA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Disc Medicine Inc. (IRON) and Mural Oncology plc (MURA). The values are adjusted to include any dividend payments, if applicable.

-10.00%0.00%10.00%20.00%30.00%40.00%50.00%AugustSeptemberOctoberNovemberDecember2025
35.82%
20.71%
IRON
MURA

Key characteristics

Sharpe Ratio

IRON:

-0.03

MURA:

0.06

Sortino Ratio

IRON:

0.51

MURA:

0.47

Omega Ratio

IRON:

1.09

MURA:

1.05

Calmar Ratio

IRON:

-0.03

MURA:

0.05

Martin Ratio

IRON:

-0.07

MURA:

0.08

Ulcer Index

IRON:

36.51%

MURA:

32.92%

Daily Std Dev

IRON:

73.12%

MURA:

49.34%

Max Drawdown

IRON:

-96.68%

MURA:

-50.58%

Current Drawdown

IRON:

-88.79%

MURA:

-31.11%

Fundamentals

Market Cap

IRON:

$1.73B

MURA:

$68.24M

EPS

IRON:

-$3.95

MURA:

-$9.02

Total Revenue (TTM)

IRON:

$0.00

MURA:

$0.00

Gross Profit (TTM)

IRON:

-$136.00K

MURA:

-$1.75M

EBITDA (TTM)

IRON:

-$95.02M

MURA:

-$97.05M

Returns By Period

In the year-to-date period, IRON achieves a -4.54% return, which is significantly lower than MURA's 28.57% return.


IRON

YTD

-4.54%

1M

-6.17%

6M

31.22%

1Y

-11.25%

5Y*

N/A

10Y*

N/A

MURA

YTD

28.57%

1M

30.19%

6M

20.00%

1Y

-5.69%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

IRON vs. MURA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IRON
The Risk-Adjusted Performance Rank of IRON is 4545
Overall Rank
The Sharpe Ratio Rank of IRON is 4343
Sharpe Ratio Rank
The Sortino Ratio Rank of IRON is 4545
Sortino Ratio Rank
The Omega Ratio Rank of IRON is 4949
Omega Ratio Rank
The Calmar Ratio Rank of IRON is 4343
Calmar Ratio Rank
The Martin Ratio Rank of IRON is 4343
Martin Ratio Rank

MURA
The Risk-Adjusted Performance Rank of MURA is 4545
Overall Rank
The Sharpe Ratio Rank of MURA is 4747
Sharpe Ratio Rank
The Sortino Ratio Rank of MURA is 4444
Sortino Ratio Rank
The Omega Ratio Rank of MURA is 4242
Omega Ratio Rank
The Calmar Ratio Rank of MURA is 4848
Calmar Ratio Rank
The Martin Ratio Rank of MURA is 4545
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

IRON vs. MURA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Disc Medicine Inc. (IRON) and Mural Oncology plc (MURA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for IRON, currently valued at -0.03, compared to the broader market-2.000.002.004.00-0.030.06
The chart of Sortino ratio for IRON, currently valued at 0.51, compared to the broader market-4.00-2.000.002.004.006.000.510.47
The chart of Omega ratio for IRON, currently valued at 1.09, compared to the broader market0.501.001.502.001.091.05
The chart of Calmar ratio for IRON, currently valued at -0.04, compared to the broader market0.002.004.006.00-0.040.05
The chart of Martin ratio for IRON, currently valued at -0.07, compared to the broader market0.0010.0020.0030.00-0.070.08
IRON
MURA

The current IRON Sharpe Ratio is -0.03, which is lower than the MURA Sharpe Ratio of 0.06. The chart below compares the historical Sharpe Ratios of IRON and MURA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.000.200.40Nov 24DecemberDec 08Dec 15Dec 22Dec 29Jan 05Jan 12Jan 19
-0.03
0.06
IRON
MURA

Dividends

IRON vs. MURA - Dividend Comparison

Neither IRON nor MURA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

IRON vs. MURA - Drawdown Comparison

The maximum IRON drawdown since its inception was -96.68%, which is greater than MURA's maximum drawdown of -50.58%. Use the drawdown chart below to compare losses from any high point for IRON and MURA. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%AugustSeptemberOctoberNovemberDecember2025
-19.65%
-31.11%
IRON
MURA

Volatility

IRON vs. MURA - Volatility Comparison

The current volatility for Disc Medicine Inc. (IRON) is 11.95%, while Mural Oncology plc (MURA) has a volatility of 16.39%. This indicates that IRON experiences smaller price fluctuations and is considered to be less risky than MURA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%AugustSeptemberOctoberNovemberDecember2025
11.95%
16.39%
IRON
MURA

Financials

IRON vs. MURA - Financials Comparison

This section allows you to compare key financial metrics between Disc Medicine Inc. and Mural Oncology plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab